Geode Capital Management, LLC Myriad Genetics Inc Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 2,016,372 shares of MYGN stock, worth $52.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,016,372

Previous 1,871,857 7.72%

Holding current value

$52.4 Million

Previous $35.8 Million 19.99%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$17.59 - $23.59 $2.54 Million - $3.41 Million	144,515 Added 7.72%	2,016,372 $43 Million
Q4 2023 Feb 13, 2024	BUY	$13.91 - $21.32 $2.02 Million - $3.09 Million	144,973 Added 8.4%	1,871,857 $35.8 Million
Q3 2023 Nov 13, 2023	BUY	$15.99 - $23.22 $991,971 - $1.44 Million	62,037 Added 3.73%	1,726,884 $27.7 Million
Q2 2023 Aug 11, 2023	BUY	$17.56 - $23.76 $1.07 Million - $1.44 Million	60,740 Added 3.79%	1,664,847 $38.6 Million
Q1 2023 May 15, 2023	BUY	$15.26 - $23.75 $1.2 Million - $1.86 Million	78,333 Added 5.13%	1,604,107 $37.3 Million

Q4 2022 Feb 13, 2023	BUY	$14.51 - $20.99 $798,108 - $1.15 Million	55,004 Added 3.74%	1,525,774 $22.1 Million
Q3 2022 Nov 14, 2022	BUY	$18.21 - $27.88 $463,954 - $710,326	25,478 Added 1.76%	1,470,770 $28.1 Million
Q2 2022 Aug 12, 2022	SELL	$16.45 - $25.88 $43,839 - $68,970	-2,665 Reduced 0.18%	1,445,292 $26.3 Million
Q1 2022 May 13, 2022	BUY	$22.67 - $28.01 $427,986 - $528,800	18,879 Added 1.32%	1,447,957 $36.5 Million
Q4 2021 Feb 11, 2022	BUY	$24.13 - $32.63 $1.19 Million - $1.61 Million	49,362 Added 3.58%	1,429,078 $39.4 Million
Q3 2021 Nov 12, 2021	BUY	$29.97 - $36.66 $478,051 - $584,763	15,951 Added 1.17%	1,379,716 $44.6 Million
Q2 2021 Aug 13, 2021	BUY	$25.39 - $32.61 $2.54 Million - $3.26 Million	100,088 Added 7.92%	1,363,765 $41.7 Million
Q1 2021 May 12, 2021	BUY	$19.92 - $31.6 $2.38 Million - $3.78 Million	119,711 Added 10.46%	1,263,677 $38.5 Million
Q4 2020 Feb 12, 2021	BUY	$12.16 - $19.77 $256,478 - $416,988	21,092 Added 1.88%	1,143,966 $22.6 Million
Q3 2020 Nov 13, 2020	SELL	$11.25 - $14.75 $256,803 - $336,698	-22,827 Reduced 1.99%	1,122,874 $14.6 Million
Q2 2020 Aug 13, 2020	BUY	$10.69 - $16.49 $439,091 - $677,326	41,075 Added 3.72%	1,145,701 $13 Million
Q1 2020 May 14, 2020	BUY	$9.78 - $29.53 $499,493 - $1.51 Million	51,073 Added 4.85%	1,104,626 $15.8 Million
Q4 2019 Feb 13, 2020	BUY	$20.93 - $35.1 $911,941 - $1.53 Million	43,571 Added 4.31%	1,053,553 $28.7 Million
Q3 2019 Nov 12, 2019	BUY	$22.08 - $47.08 $254,781 - $543,256	11,539 Added 1.16%	1,009,982 $28.9 Million
Q2 2019 Aug 14, 2019	BUY	$22.67 - $35.0 $1.62 Million - $2.51 Million	71,670 Added 7.73%	998,443 $27.7 Million
Q1 2019 May 14, 2019	BUY	$26.93 - $34.7 $1.27 Million - $1.64 Million	47,324 Added 5.38%	926,773 $30.8 Million
Q4 2018 Feb 13, 2019	BUY	$27.23 - $45.56 $2.82 Million - $4.72 Million	103,528 Added 13.34%	879,449 $25.6 Million
Q3 2018 Nov 13, 2018	BUY	$37.57 - $50.34 $1.61 Million - $2.16 Million	42,900 Added 5.85%	775,921 $35.7 Million
Q2 2018 Aug 14, 2018	BUY	$27.75 - $40.17 $1.58 Million - $2.28 Million	56,762 Added 8.39%	733,021 $27.4 Million
Q1 2018 May 15, 2018	BUY	$28.83 - $41.01 $1.71 Million - $2.44 Million	59,463 Added 9.64%	676,259 $20 Million
Q4 2017 Feb 13, 2018	SELL	$28.45 - $37.14 $1.21 Million - $1.58 Million	-42,631 Reduced 6.46%	616,796 $21.2 Million
Q3 2017 Nov 14, 2017	BUY	$24.01 - $36.2 $133,303 - $200,982	5,552 Added 0.85%	659,427 $23.9 Million
Q2 2017 Aug 14, 2017	BUY	N/A	653,875	653,875 $16.9 Million

Others Institutions Holding MYGN

# of Institutions

195

Shares Held

94.2M

Call Options Held

280K

Put Options Held

14.3K

View Full List

About MYRIAD GENETICS INC

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $2.09B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

More about MYGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Myriad Genetics Inc Transaction History